Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice

British Journal of Clinical Pharmacology

Volumn 62, Issue 5, 2006, Pages 560-566

  Moltó, José ^a,c   Blanco, Asunción ^a   Miranda, Cristina ^a   Miranda, José ^a   Puig, Jordi ^a   Valle, Marta ^b,c   DelaVarga, Meritxell ^a   Fumaz, Carmina R ^a   Barbanoj, Manuel José ^b,c   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antiretroviral agents; Clinical practice; Drug concentrations; HIV infection; Interindividual variability

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33749987244     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02694.x     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fhurer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 238: 853-60.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997; 337: 725-33.
3. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35-F43.
4. Barlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antirretroviralnaive HIV-1 infected adults. AIDS 2001; 15: 1369-77.
5. Back D, Gatti G, Fletcher C, Garraffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl. 1): S5-S37.
6. Murphy R. Antirretroviral therapy in patients with suboptimal virologic suppression. AIDS Rev 1999; 1: 205-12.
7. Drusano GL, Biello JA, Stein DS, Nessly M, Meibohm A, Emini EA, Deustch P, Condra J, Chodakewitz J, Holder DJ. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis 1998; 78: 360-7.
8. Reijers MH, Weigel HM, Hart AA, Ten Kate RW, Mulder JW, Reiss P, Schuitemaker H, Hoetelmans RM, Weverling GJ, Lange JM. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000; 14: 59-67.
9. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3: 215-20.
10. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
11. Gieschke R, Fotteler B, Buss N, Steiner JL. Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37: 75-86.
12. Burger D, Hugen PW, Aarnoutse RE, Hoetelmans R, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME, Lange JM, ATHENA Study Group. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25: 73-80.
13. Sadler BM, Guillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001; 45: 30-7.
14. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46: 2926-32.
15. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71-5.
16. Veldkamp AL, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals. AIDS 2001; 15: 1089-95.
17. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45.
18. Gonzalez de Requena D, Bonora S, Canta F, Marrone R, D'Avolio A, Sciandra M, Milia M, Di Garbo A, Sinicco A, Di Perri G. Atazanavir Ctrough is Associated with Efficacy and Safety: Definition of Therapeutic Range. 12th Conference on Retroviruses and Opportunistic Infections. Boston February 2005 [Abstract 645].
19. Torti C, Quiros-Roldan E, Tirelli V, Regazzi-Bonora M, Moretti F, Pierotti P, Orani A, Maggi P, Cargnel A, Patroni A, De Luca A, Carosi G. Lopinavir plasma levels in salvage regimens by a population of highly active antiretroviral therapy-treated HIV-1-positive patients. AIDS Patient Care Stds 2004; 18: 629-34.
20. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp ECM, Mairuhu ATA, Beijnen JH. Subtherapeutic antiretroviral concentrations in routine clinical outpatient HIV care. Ther Drug Monit 2003; 25: 367-73.
21. Langmann P, Zilly M, Weissbrich B, Schlor C, Vath T, Richter E, Klinker H. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Eur J Med Res 2000; 5: 59-62.
22. Burger D, Hughen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aaranoutse R, Lange J, ATHENA Study Group. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naïve HIV-infected individuals. AIDS 2003; 17: 1157-65.
23. Sarasa-Nacenta M, López-Púa Y, López-Cortés LF, Mallolas J, Gatell JM, Carne X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromat B Biomed Sci Appl 2001; 763: 53-9.
24. Droste JAH, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-91.
25. Back DJ, Blashke TF, Boucher C, Burguer D, Fletcher C, Flexner C, Gerber J, Shapiro J. Optimising TDM in HIV Clinical Care: a Practical Guide to Performing Therapeutic Drug Monitoring (TDM) for Antiretroviral Agents [online]. Available from URL http://www.hivpharmacology.com Last accessed 10 January 2005.
26. de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu ATA, van Gorp ECM, Huitema AD, Beijnen JH. Incidence and risk factors for nevirapine- associated rash. Eur J Clin Pharmacol 2003; 59: 457-62.
27. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating antiretroviral therapy. J Infect Dis 2005; 191: 339-47.
28. Kapelhoff BS, van Leth F, Robinson PA, MacGragor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10: 489-98.
29. Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient variability and low intrapatient variability. Ther Drug Monit 2001; 23: 394-8.